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We found that ZBTB2, a POK family transcription factor, is a
potent repressor of the ARF-HDM2-p53-p21 pathway impor-
tant in cell cycle regulation. ZBTB2 repressed transcription of
the ARF, p53, and p21 genes, but activated the HDM2 gene. In
particular, ZBTB2 repressed transcription of the p21 gene by
acting on the two distal p53 binding elements and the proximal
Sp1 binding GC-box 5/6 elements. ZBTB2 directly interacted
with Sp1 via its POZ domain and zinc fingers, which was impor-
tant in the repression of transcription activation by Sp1. ZBTB2
and Sp1 competed with each other in binding to the GC-box 5/6
elements and the two p53 binding elements. ZBTB2 directly
interacted with p53 via its zinc fingers, inhibiting p53 binding
and repressing transcription activation by p53. The POZ
domain, required for transcription repression, interacted with
corepressors such as BCoR, NCoR, and SMRT. The interactions
deacetylated histones Ac-H3 and -H4 at the proximal promoter.
Although ectopic ZBTB2 stimulated cell proliferation, knock-
down of ZBTB2 expression decreased cell proliferation and
DNA synthesis. Overall, our data suggest that ZBTB2 is a poten-
tial proto-oncogenic master control gene of the p53 pathway
and, in particular, is a potent transcription repressor of the cell
cycle arrest gene p21 by inhibiting p53 and Sp1.
The POZ domain is an evolutionarily conserved protein-
protein interaction motif found in many cellular regulatory
proteins (1, 2). POZ domain genes, first identified in Dro-
sophila and poxvirus, have since been found in organisms
ranging from yeast to humans (3, 4). As many as 184 known
human proteins, 96 Drosophila proteins, and 137 Caenorh-
abditis elegans proteins are estimated to contain the POZ
domain.
POZdomain proteins are involved inmany critical cellular pro-
cesses such as apoptosis (5), development (6, 7), ion channel activ-
ity (4), oncogenesis (8–10), and transcription (10–16). In particu-
lar, some of the POZ domain Kru¨ppel-like zinc finger (POK)3
proteins are the major determinants of development, differen-
tiation, and oncogenesis. PLZF-null mice display severe defects
in limb development and germ stem cell maintenance (7, 17). T
helper-inducing POZ/Kru¨ppel-like factor (Th-POK/cKrox)
has been recently reported as a master regulator of T-cell line-
age commitment (18). BCL-6, PLZF, and HIC1 have been
implicated in non-Hodgkin lymphoma, acute promyelocytic
leukemia, and spontaneous malignant tumors, respectively (8,
9, 19). Recently, FBI-1 (also called Pokemon) has been shown to
act as a proto-oncogene by repressing transcription of the ARF
gene, causing down-regulation of p53 and promoting onco-
genic cellular transformation (10).
The most striking property of some POZ domain transcrip-
tion factors is their ability to repress transcription via their POZ
domains (10–16, 20), although a few POZ domain transcrip-
tion factors activate transcription (21, 22). This characteristic
probably underlies many biological processes controlled by
these factors. The ability of the domain to interact with key
regulatory proteins such as corepressor proteins and other
transcription factors appears to be important for repression. In
particular, the POZ domains of human BCL-6, FBI-1, HIC-1,
and PLZF interact with BCoR, histone deacetylase, mSin3A,
and SMRT/N-CoR (12–16, 20, 23).
The cyclin-dependent kinase inhibitor p21 is a major player
in cell cycle arrest in mammalian cells and the downstream cell
cycle regulator of the ARF-HDM2-p53-p21 pathway (Refs. 24
and 25 and references therein). The p21 gene, mainly regulated
at the transcriptional level, is a transcriptional target of tumor
suppressor p53 and plays a crucial role in mediating growth
arrest when cells are exposed to DNA-damaging agents (Refs.
24–26 and references therein).Overexpression of p21 results in
G1-, G2-, or S-phase arrest upon exposure to DNA-damaging
agents (27–29).Whereas induction of p21 predominantly leads
to cell cycle arrest, repression of p21 may have a variety of
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outcomes depending on the cellular context (Ref. 26 and refer-
ences therein, and Ref. 27). Aside from p53, a variety of other
factors, including Smads, AP2, STAT, BRCA1, E2F-1/E2F-3,
and C/EBP and -, activate the transcription of p21. In addi-
tion to its role in responding toDNAdamage, p21 has also been
implicated in terminal differentiation, replicative senescence,
and protection from p53-dependent and -independent apopto-
sis (Ref. 26 and references therein).
Sp1 family transcription factors that bind at the proximal
promoter (bp120 to50) of the p21 gene represent another
group of major regulators that affect p21 gene expression (Ref.
26 and references therein). Sp1 is one of the best characterized
transcription factors that bind to GC-rich DNA sequences in
numerous cellular and viral genes (Refs. 30 and 31 and refer-
ences therein). The six Sp1 binding GC-boxes of the p21 gene
proximal promoter have been shown to be important;mutation
of the sites not only significantly affects transcription but also
disrupts synergistic transcription activation by Sp1, p53, and
other signals that regulate p21 gene transcription (26, 32).
Among the six GC-boxes, GC-box 3mediates p21 induction by
various agents such as transforming growth factor-, butyrate,
histone deacetylase inhibitor trichostatin A, lovastatin, and
Ca2. In contrast, GC-boxes 1 and 2 mediate transcriptional
activation by phorbol esters and okadaic acid, tumor suppres-
sor protein BRCA1, and gut-enriched Kru¨ppel-like factor
(GKLF, KLF4). To date, no specific role has been attributed to
the most proximal and overlapping GC-boxes 5 and 6 (Ref. 26
and references therein). Together, these observations suggest
that the specificity of utilizing different proximal GC-boxes
under different p21 gene regulation conditions is important.
In this article, we investigated whether a novel POK family
protein, ZBTB2, could regulate any components of the ARF-
HDM2-p53-p21 pathway, and examined the mechanisms and
physiological consequences of ZBTB2 action. ZBTB2 repressed
transcription of theARF, p53, and p21 genes, and potently acti-
vated the HDM2 gene, which overall down-regulates the p53
pathway significantly. ZBTB2 increased cell proliferation sig-
nificantly. Our data suggest that ZBTB2 may be a master regu-
lator of the p53 pathway and may play a critical role in impor-
tant biological processes controlled by p21 and other genes of
the p53 pathway.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Reagents—The p21-Luc plasmid
was kindly provided by Dr. Yoshihiro Sowa of the Kyoto Perpe-
tural University ofMedicine (Kyoto, Japan). The various pGL2-
p21-Luc, pGL2-p53-Luc, pGL2-ARF-Luc, pGL2-HDM2-Luc,
pcDNA3.1-p53, pcDNA3.1-Sp1, pG5-5x(GC-box)-Luc, pPac-
Sp1, expression vectors of corepressors, andVP16 corepressors
we used have been reported elsewhere (20, 22). The
pcDNA3.1-ZBTB2 and pcDNA3.1-ZBTB2POZ plasmids
were prepared by cloning cDNA fragments into pcDNA3.1
(Invitrogen). The GAL4-POZZBTB2 plasmid was prepared by
cloning cDNA fragment encoding the POZ domain (amino
acids 24–117) into pBIND (Promega). To prepare recombinant
GST-POZZBTB2 and GST-ZFZBTB2 proteins, cDNA frag-
ments encoding the POZ domain (amino acids 24–117) and
zinc fingers (amino acids 254–468) were cloned into pGEX4T3
(Amersham Biosciences). The pPac-PL-ZBTB2 plasmid was
prepared by cloning the cDNA fragments into pPac-PL. All
plasmid constructs were verified by sequencing.
Antibodies against p21, p53, Sp1, GAPDH, Myc tag, FLAG
tag, Ac-H3, Ac-H4, and HDAC3 were purchased from Upstate
(Charlottesville, VA), Chemicon (Temecula, CA), Calbiochem,
and Santa Cruz Biotechnology (Santa Cruz, CA), respectively.
Most of the chemical reagents were purchased from Sigma.
Cell Cultures—HEK293A, HeLa, MB352, and CV-1 cells
were cultured in Dulbecco’s modified Eagle’s medium (Invitro-
gen) supplemented with 10% fetal bovine serum (Invitrogen).
Saos-2 cells were cultured inMcCoy’s 5Amedium (Invitrogen)
supplemented with 15% fetal bovine serum. Drosophila SL2
cells were cultured in Schneider’sDrosophilamedium (Invitro-
gen) supplemented with 10% fetal bovine serum.
Transcriptional Analysis of ARF, HDM2, p53, and p21 Genes—
The pGL2-ARF-Luc, pGL2-HDM2-Luc, pGL2-p53-Luc, and
various pGL2-p21-Luc promoter reporter fusion plas-
mids as well as pcDNA3.1-ZBTB2, pcDNA3.1-ZBTB2POZ,
pcDNA3.1-p53, pcDNA3.1-Sp1, and pCMV-LacZ in various
combinations were transiently transfected into several cell
lines such as HEK293A, HeLa, MB352, Saos-2, and CV-1
using Lipofectamine Plus reagent (Invitrogen). After 24–36
h of incubation, cells were harvested and analyzed for lucif-
erase activity. Reporter activity was normalized with
cotransfected -galactosidase activity for transfection
efficiency.
RT-PCR of ZBTB2 mRNA Expression in FVB Mice or Cells—
Total RNAwas isolated from brain, heart, liver, muscle, kidney,
spleen, brown adipose tissues, andwhite adipose tissues or cells
using TRIzol reagent (Invitrogen). Synthesis of cDNAwas done
using 5 g of total RNA, random hexamer (10 pmol), and
Superscript reverse transcriptase II (200 units) in 20 l using a
reverse transcription kit (Invitrogen). The following oligonu-
cleotide PCR primers were used: murine Zbtb2 (forward,
5-CCAACCATGGACTTATTCTA-3; reverse, 5-TTCATC-
CTGGATGCCTGTGG-3), -actin (forward, 5-ATGGATG-
ACGATATCGCTGC-3, reverse, 5-CACACTGTGCCCAT-
CTACGA-3), Human ZBTB2 (forward, 5-GATCGGATCC-
GATTTGGCCAACCATGGA-3; reverse, 5-GATCCTCGA-
GAGAAAAGGCTCCCTGGCT-3), p21 (forward, 5-ATGT-
CAGAACCGGCTGGGGATGTCC-3, reverse, 5-TTAGGG-
CTTCCTCTTGGAGAAGATC-3), andGAPDH (forward, 5-
ACCACAGTCCATGCCATCAC-3; reverse, 5-TCCACCA-
CCCTGTTGCTGTA-3).
Western Blot Analysis—Cells were harvested and lysed in
RIPA buffer (50 mM Tris-HCl, pH 8.0, 1% Nonidet P-40, 0.25%
sodium deoxycholic acid, 150mMNaCl, 1mMEGTA, complete
Mini-Protease mixture). Cell extracts (40 g) were separated
using 12% SDS-PAGE gel electrophoresis, transferred onto
Immun-BlotTM polyvinylidene difluoride membranes (Bio-
Rad), and blocked with 5% skimmilk (BD Biosciences). Blotted
membranes were incubated with antibodies against FLAG tag
(Sigma), GAPDH (Chemicon), p21, p53, Sp1, Myc tag, (Santa
Cruz Biotechnology) and then incubated with horseradish per-
oxidase-conjugated anti-mouse and anti-rabbit secondary anti-
body (Vector Laboratory). Protein bands were visualized with
ECL solution (PerkinElmer Life Sciences).
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Knock-down of ZBTB2 mRNA by siRNA—Four siRNA
against ZBTB2 mRNA were designed and purchased from
Dharmacon (Lafayette, CO): siZBTB2-1, 5-GAUCAUCAGU-
UGAGACAAGUU-3, 5-PCUUGUCUCAACUGAUGAU-
CUU-3; siZBTB2-2, 5-CAGGUGAAUCGGACAAAUAUU-
3, 5-PUAUUUGUCCGAUUCACCUGUU-3; siZBTB2-3,
5-CGACCCGGUUCGAUUAGAAUU-3, 5-PUUCUAA-
UCGAACCGGGUCGUU-3; and siZBTB2-4, 5-AGACGA-
AGGGCGAUCCAUUUU-3, 5-
PAAUGGAUCGCCCUUCGUC-
UUU-3. The siRNA (200 pmol)
were transfected into HEK293A
cells using Lipofectamine 2000
(Invitrogen). After transfection,
cells were harvested, and total
RNA was prepared. RT-PCR anal-
ysis of mRNA was performed as
described above.
Chromatin Immunoprecipitation
(ChIP) Assays—The molecular
interaction between ZBTB2 and
p53 or Sp1 on the p21 gene pro-
moter and histone modification at
the p21 proximal promoter in
HEK293A, Saos-2, and Drosophila
SL2 cells were analyzed by following
the standard ChIP assay protocol, as
described elsewhere (20, 22).
PCR of chromatin immunopre-
cipitated DNA was carried out
using oligonucleotide primer sets
designed to amplify the upstream
regulatory regions and proximal
promoter region of the p21 gene.
p53 RE-1 binding primers (bp,
2307–1947), forward, 5-TGC-
TTGGGCAGCAGGCTGTG-3, re-
verse, 5-GCAACCATGCACTT-
GAATGT-3; p53 RE-2 binding
primers (bp, 1462–1128), for-
ward, 5-TGTCCTCCCACCCC-
TACCTGG-3, reverse, 5-AGA-
AATGAGTGATGTGTC-3; pro-
ximal GC-boxes ChIP primers
(bp, 261 to approximately 39),
forward, 5-GGCTCACTTCGTG-
GGGAAAT-3, reverse, 5-CACA-
AGGAACTGACTTCGGC-3. To
analyze histone H3 and H4 modifi-
cation at the proximal promoter
(bp, 133 to 100), forward 5-
GCGCTGGGCAGCCAGGAGCC-
3 and reverse 5-CGCTCTCTCA-
CCTCCTCT-3 primers were used.
Immunoprecipitation Assays—
Cells were washed, pelleted, and
resuspended in a lysis buffer supple-
mented with protease inhibitors (20
mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton
X-100). Cell lysate was precleared, and the supernatant was
incubated overnight with anti-FLAG antibody on a rotating
platform at 4 °C, followed by incubation with protein A-
Sepharose Fast Flow beads. Beads were collected, washed, and
resuspended in equal volumes of 5 SDS loading buffer. Immu-
noprecipitated proteins were separated with 12% SDS-PAGE.
Western blot assay was performed as described above.
FIGURE 1. ZBTB2 represses transcription of the ARF, p53, and p21 genes, and activates HDM2 transcrip-
tion. A, transcription regulation of the genes of the p53 pathway by ZBTB2. Expression vectors of ZBTB2 and
reporter plasmids were transiently co-transfected into HEK293A cells and luciferase activity was measured.
Error bars represent standard deviations. B, RT-PCR andWestern blot analysis of HEK293A cells infected either
with control adenovirus (dl324) or recombinant adenovirus overexpressing ZBTB2 (dl324-ZBTB2). C, knock-
down and RT-PCR analysis of ZBTB2mRNAof HEK293A cells by four different siRNAs. siRNA-2 resulted in the
most efficient knock-down. D, Western blot analysis of cell lysates prepared from the HEK293A cells
transfected with negative control scrambled siRNA (N.C.) or siZBTB2 RNA-2. E, transcription assays. Knock-
down of ZBTB2 mRNA-derepressed p21 gene expression. pGL2-p21-Luc (2.3 kb) reporter plasmid and
four different siRNA were transiently co-transfected into HEK293A cells and analyzed for luciferase activ-
ity. F, structures of various p21 gene promoter constructs tested.G, transcription assays. ZBTB2 expression
vector and pGL2-p21-Luc reporter plasmid with a variable upstream sequence were transiently co-trans-
fected into HEK293A cells and analyzed for luciferase activity.
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Mammalian Two-hybrid Assays—CV-1 cells were co-trans-
fected with pG5-Luc, pGal4-POZZBTB2, pVP16-corepressors,
and pCMV-LacZ. After 24 h of transfection with Lipofectamine
Plus (Invitrogen), CV-1 cells were harvested and assayed for lucif-
erase activity. Luciferase activity was
then normalized with cotransfected
-galactosidase activity.
GST Fusion Protein Purification,
in Vitro Transcription and Trans-
lation of Corepressors, p53, or Sp1,
and Pull-down Assays—Recombi-
nant GST, GST-POZZBTB2, and
GST-ZFZBTB2 fusion proteins were
prepared from Escherichia coli BL21
(DE3) grown for 5 h at 37 °C in a
medium containing 1 mM isopropyl
1-thio--D-galactopyranoside. E. coli
were lysedandpurifiedusingglutathi-
one-agarose 4 bead affinity chroma-
tography (Peptron, Taejeon, Korea).
The purified proteins were then
resolved with 12% SDS-PAGE to
quantitate and assess purity. Core-
pressor, p53, and Sp1 polypeptides
were prepared by incubating 1 g of
pcDNA3.0-corepressor, pcDNA3.1-
p53, and pcDNA3.1-Sp1 expression
plasmid with TNT Quick-coupled
Transcription/Translation Extract
(Promega) containing 40 l of TNT
Quick Master Mix and 2 l of
[35S]methionine (1175.0 Ci/mol)
(PerkinElmer Life Sciences) at 30 °C
for 90 min. Polypeptide expression
levels were then analyzed by running
1l of the total mixture through 12%
SDS-PAGE and autoradiography.
For GST fusion protein pull-
down assays, GST fusion protein-
agarose bead complexes were incu-
bated with 10 l of in vitro
translated [35S]methionine-labeled
corepressors, p53, and Sp1 polypep-
tides at 4 °C for 4 h in HEMGbuffer.
The reaction mixtures were centri-
fuged, pellets were rinsed, and the
bound proteins were separated
using 12% SDS-PAGE. Gels were
then exposed to x-ray film using an
image-intensifying screen (Kodak).
Preparation of Recombinant Ade-
novirus Overexpressing ZBTB2—
ZBTB2 cDNA was cloned into the
adenovirus E1 shuttle vector pCA14
(Microbix, Ontario, Canada), to
generate pCA14-ZBTB2. The
pCA14-ZBTB2 shuttle vector was
linearized by XmnI digestion, and
the adenovirus vector vmdl324Bst (from Dr. Verca at the Uni-
versity of Fribourg, Switzerland) containing the Ad5 genome
deleted in the E1 and E3 regions was also linearized with BstBI
digestion. The linearized pCA14-ZBTB2 and vmdl324Bst
ZBTB2, a Novel Master Regulator of the p53 Pathway
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digested with BstBI were co-transformed into E. coli BJ518 for
homologous recombination. Proper homologous recombinant
adenoviral plasmid was digested with PacI and transfected into
HEK293 cells to generate the adenovirus expressing ZBTB2
(dl324-ZBTB2). Propagation and titration of the recombinant
virus were carried out by standardmethods. PCR amplification
and DNA sequencing using primers specific to ZBTB2 con-
firmed the adenovirus genotype.
Electromobility Shift Assays (EMSA)—EMSAs were carried
out as described previously (20, 22, 33). The probe sequences of
Sp1 response elements on the p21 gene proximal promoter or
the sequences of p53 response elements on the p21 gene distal
promoter used in EMSA were as follows (only top strands are
shown): GC-box 1, 5-GATCGGGAGGGCGGTCCCG-3;
GC-box 2, 5-GATCTCCCGGGCGGCGCG-3; GC-box 3, 5-
GATCCGAGCGCGGGTCCCGCCTC-3; GC-box 4, 5-GAT-
CCTTGAGGCGGGCCCG-3; GC-box 5/6, 5-GATCGGGCG-
GGGCGGTTGTATATCA-3; p53RE-1, 5-GATCCGTTAGA-
GGAAGAAGACTGGGCATGTCTG-3; and p53 RE-2, 5-
GATCCATCAGGAACATGTCCCAACATGTTGAGCTC-3.
Oligonucleotide Pull-down Assays—HEK293A cells were
lysed in HKMG buffer (10 mM HEPES, pH 7.9, 100 mM KCl, 5
mMMgCl2, 10%glycerol, 1mMdithiothreitol, and 0.5%Nonidet
P-40). Cellular extracts were incubated with 1 g of biotiny-
lated double-stranded oligonucleotides (p53 RE-1, p53 RE-2,
and Sp1 GC-box 5/6) for 16 h. The sequences of the oligonu-
cleotides are as follows (only top strands are shown): Sp1 GC-
box 5/6, 5-CCTTGAGGCGGGCCCGGGCGGGGCGGTTG-
TATATCAGGGC-3; p53 RE-1, 5-GTCAGGAACATGTCC-
CAACATGTTGAGCTC-3; p53 RE-2, 5-TAGAGGAAGA-
AGACTGGGCATGTCTGGGCA-3. To collect DNA-
boundproteins, themixtureswere incubatedwith streptavidin-
agarose beads for 2 h, washed with HKMG buffer, and
precipitated by centrifugation. The precipitate was analyzed by
Western blot assay as described above.
FACS Analyses—HEK293A cells were transfected with
pcDNA3.1-ZBTB2 expression vector or siZBTB2 RNA in the
presence or absence of p53 expression vector. Cells were
washed, fixed with methanol, and stained with 50 g/ml of
propidium iodide in 100 g/ml of ribonuclease A for 30 min at
37 °C in the dark. DNA content, cell cycle profiles, and forward
scatter were analyzed by FACSCalibur (BD Biosciences) with
emission detection at 488 nm (excitation) and 575 nm (peak
emission). Data were analyzed using ModFit LT 2.0 (Verity
Software House, Inc., ME) and WindMDI 2.8 (Joseph Trotter,
The Scripps Research Institute).
MTT Assays—Confluent HEK293A cells grown on 10-cm
culture dishes were transfected with pcDNA3.1-ZBTB2
expression vector or siZBTB2 RNA in the presence or absence
of p53 expression vector. Cells (1.5 105 cells) were transferred
to 6-well culture dishes and grown for 0–6 days. At 0, 2, 4, and
6 days, cells were incubated for 1 h at 37 °C with 500 l/well
MTT (2 mg/ml). Precipitates were dissolved with 1 ml of di-
methyl sulfoxide. Cellular proliferation was determined from
the conversion of MTT to formazan using a SpectraMAX 250
(Molecular Device Co.) at 570 nm. p value was calculated using
the statistical analysis programSPSS (Statistical Package for the
Social Sciences) (Chicago, IL).
Preparation of Anti-ZBTB2 Antibody—To obtain a rabbit
polyclonal antibody against ZBTB2 protein, one white rabbit
was immunized subcutaneously with a synthetic peptide
(amino acids 500–514 of ZBTB2; VLASIKKEQETVLLD) three
times at 3-week intervals. Blood was collected, incubated at
37 °C for 90 min, and centrifuged. The supernatant was incu-
batedwith the proteinA/G-agarose beads (Santa Cruz Biotech-
nology). The beads were collected and washed, and the anti-
body was eluted. The titer of the antibody was tested by
Western blot assay of the HEK293A cells transfected with the
pcDNA3.1-ZBTB2 overexpression vector.
RESULTS
ZBTB2, aNovel POKProtein, Represses Transcription of ARF,
p53, and p21Genes of the p53 Pathway but Activates Transcrip-
tion of HDM2—ZBTB2 cDNA encodes a protein composed of
514 amino acids (supplemental Fig. S1). ZBTB2 contains an
N-terminal POZ domain at amino acids 24 to 117 and four zinc
fingers at the C terminus. ZBTB2 mRNA was expressed in all
male FVBmouse tissues examined, and was particularly high in
the spleen (supplemental Fig. S2D). SAGE analysis by the Can-
cer Genomic Anatomy Project (CGAP) showed that ZBTB2
mRNA expression is higher in cancers derived from the retina,
thyroid, liver, peritoneum, ovary, and muscle compared with
normal tissues (nci.nih.gov). Immunocytochemistry in
HEK293A cells detected ZBTB2 in both the cytoplasm and
nuclear speckles (supplemental Fig. S2E). Although the calcu-
lated molecular mass of ZBTB2 is 57 kDa,Western blot anal-
ysis of the HEK293A cell lysate transfected with the
pcDNA-FLAG-ZBTB2 expression vector yielded a 75-kDa
FIGURE 2. ZBTB2 represses transcription activation by Sp1 on theminimal p21 promoter and pG5-5x(GC)-Luc. ZBTB2 competes with Sp1 to bind to the
proximal GC-box 5/6. ZBTB2 interactswith Sp1 toweakly inhibit Sp1 binding.A and B, Sp1 activated transcription of pGL2-p21-Luc (131 bp) andpG5-5x(GC)-
Luc, and ZBTB2 repressed transcriptional activation by Sp1. C, EMSA. The 32P-labeled Sp1 binding GC-box probes were incubated with GST-ZFZBTB2 (0.5 g)
and separated by 4%nondenaturing PAGE.D, ChIP assay inDrosophila SL2 cells transfectedwith pGL2-p21-LucMt, pPac PL-Sp1, and/or pPac PL-FLAG-ZBTB2.
ZBTB2 couldnotbind to themutatedproximal promoter.X,mutatedGC-box5/6. E, ChIP assayof ZBTB2bindingon thep21Wtpromoter inDrosophila SL2 cells.
Cells were transfected with pGL2-p21-Luc Wt, pPac PL-Sp1, and increasing amounts of pPac PL-FLAG-ZBTB2. F, ChIP assay of the endogenous p21 gene in
humanHEK293A cells transfectedwith pcDNA3-FLAG-ZBTB2. ZBTB2 competedwith Sp1 to bind to the proximal promoter and inhibited Sp1 binding, but not
in the 3-untranslated region. Bottom, histogram of ChIP assays. G, co-immunoprecipitation of ZBTB2 and Sp1. Cell lysates prepared from HEK293A cells
transfected with the pcDNA3-FLAG-ZBTB2 expression vector were co-immunoprecipitated using anti-FLAG antibody (Ab) and analyzed by Western blotting
using anti-Sp1 antibody. H, in vitro GST fusion protein pull-down assays. Recombinant GST, GST-POZZBTB2, or GST-ZFZBTB2 was incubated with [35S]methi-
onine-labeled Sp1, pulled down, and resolved by a 10% SDS-PAGE. Input, 10% of the Sp1 added in the binding reactions. I, ChIP assay of endogenous ZBTB2
binding to theproximalGC-box 5/6 elements of endogenousp21 inHEK293Acells. ChIP PCRprimer sets are as in F. J, oligonucleotidepull-downassayof ZBTB2
binding to the proximal GC-box 5/6 elements of the p21 gene promoter. HEK293A cell extracts were incubated with biotinylated double-stranded oligonu-
cleotides. Themixtures were further incubated with streptavidin-agarose beads and precipitated by centrifugation. The precipitate was analyzed byWestern
blot (WB) assay using antibody against ZBTB2. IP, immunoprecipitation.
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band, suggesting the possibility of post-translational modi-
fication of the protein.
Recently, several reports have implicated POZ domain pro-
teins such as FBI-1, BCL-6, and Miz-1 in cell cycle regulation
(10, 21). We investigated whether ZBTB2 regulates expression
of the genes (ARF, HDM2, p53, and p21) of the p53 pathway,
which is important in cell cycle regulation. In humanHEK293A
cells, ZBTB2 repressed transcrip-
tion of three genes (ARF, p53, and
p21) of the p53 pathway by more
than 60–80%, and repression was
particularly effective in the p21
gene. In contrast, ZBTB2 increased
transcription ofHDM2, which could
induce degradation of p53 (Fig. 1A)
(33).
Because all of the transcriptional
regulatory effects of ZBTB2 on the
p53 pathway converged onto
expression of the p21 gene, an
important negative regulator of cell
cycle progression, we investigated
the molecular mechanisms of tran-
scriptional regulation of the p21
gene in detail. RT-PCR andWestern
blot analysis of HEK293A cells
infected with either control adeno-
virus or recombinant virus overex-
pressing ZBTB2 showed that
ZBTB2 repressed p21 gene expres-
sion (Fig. 1B). Knock-down of ZBTB
mRNA by RNA interference with
four different siRNAs also resulted
in derepression of p21 gene tran-
scription, particularly with ZBTB2
number 2 siRNA (Fig. 1, C–E).
Taken together, these data suggest
that ZBTB2 is amajor negative tran-
scription regulator of the p53 path-
way and particularly of the p21 gene.
Furthermore, we mapped the cis-
regulatory elements of the p21 gene
promoter responsible for transcrip-
tional repression by ZBTB2. Tran-
scription assays indicate that ZBTB2
can repress transcription by acting
on the small proximal regulatory
element concentrated with Sp1
binding GC-boxes (bp, 133 to
approximately 30) (Ref. 26 and
references therein). We observed
more potent repression with the
longer promoter constructs con-
taining the distal p53 binding ele-
ments (Fig. 1, F and G).
ZBTB2Competeswith Sp1 to Bind
to the Proximal Promoter GC-box
5/6 of the p21 Gene and ZBTB2
Interacts with Sp1—The above data suggested that Sp1 and the
GC-boxes could be involved in repression by ZBTB2. Accord-
ingly, we tested whether ZBTB2 could repress transcriptional
activation by Sp1 on the short p21 proximal promoter and arti-
ficial pG5-5x(GC)-Luc with the well characterized Sp1 binding
GC-box (34) in HEK293A cells. Sp1 activated transcription of
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the reporter genes and ZBTB2 repressed transcriptional activa-
tion by Sp1 on the two promoter constructs (Fig. 2, A and B).
Often, transcription repression can be achieved by binding
competition at the same DNA element or inhibition of tran-
scription factor binding activity by protein-protein interac-
tions. EMSA and ChIP in Drosophila SL2 cells transiently co-
transfected with expression vectors of ZBTB2 and Sp1 and
pGL2-p21-LucWt (2.3 kb) or pGL2-p21-LucMt GC-box 5/6
(2.3 kb) showed that ZBTB2 zinc fingers and Sp1 could bind
to the proximal Sp1 binding GC-box 5/6 (Fig. 2, C–E). Muta-
tion of the element prevented ZBTB2 from binding. Ectopic
ZBTB2 weakly decreased Sp1 binding (Fig. 2D). Overall, the
data imply that Sp1 and ZBTB2 may compete with each other
to bind to the element. In human HEK293A cells, ectopic
ZBTB2 binds to the proximal promoter of the endogenous p21
gene but not to the control 3-untranslated region. ZBTB2
competed with Sp1 to bind to the region and decreased Sp1
binding in a dose-dependent manner (Fig. 2F).
ChIP assays in Drosophila SL2 cells showed that although
ZBTB2was not able to bind to themutatedGC-box 5/6, ZBTB2
still appeared to weakly inhibit Sp1 binding to the proximal
promoter region, probably through an Sp1-ZBTB2 interaction
(Fig. 2D). Co-immunoprecipitation andWestern blot assays of
the HEK293A cellular extract trans-
fected with the FLAG-ZBTB2
expression vector showed that Sp1
and ZBTB2 interacted with each
other in vivo (Fig. 2G). GST fusion
protein pull-down assays also dem-
onstrated that both the POZ and ZF
domains of ZBTB2 interact directly
with Sp1 (Fig. 2H). ZBTB2 not only
competed with Sp1 to bind to the
proximal GC-box 5/6 elements, but
also interacted with Sp1 to inhibit
Sp1 binding, repressing transcrip-
tion of the p21 gene.
We also examinedwhether endog-
enous ZBTB2 binds the proximal
GC-box 5/6 of the endogenous p21
gene by ChIP and oligonucleotide
pull-down assays using antibody
against ZBTB2. Apparently, endoge-
nous ZBTB2 binds to the proximal
promoter GC-box 5/6 of the endoge-
nous p21 gene (Fig. 2, I and J).
ZBTB2 Represses Transcription
of p21 through Binding Competi-
tion between ZBTB2 and p53 on
the Distal p53 Binding Elements and ZBTB2 Interacts with
p53—Because more robust transcription repression was
observed with pGL2-p21-Luc 2.3-kb and 1.5-kb
constructs compared with pGL2-p21-Luc 131 bp (Fig. 1, F
andG), we suspected that other repressionmechanisms involv-
ing p53 and/or distal p53 binding elements might be possible.
ZBTB2 repressed transcription of pGL2-p21-Luc by 50% in
MB352 cells lacking endogenous p53. Ectopic p53 increased
p21 gene expression, which was repressed by ZBTB2 (Fig. 3A).
In HEK293 A cells, treatment with the DNA damaging agent
etoposide increased p21 gene expression by inducing p53,
whichwas again repressed by ZBTB2 (Fig. 3B). Additional tran-
scriptional analysis of pGL2–6x(p53RE)-Lucwith five copies of
the p53 binding elements of the p21 gene in the proximal pro-
moter showed that ZBTB2 blocked transcription activation by
p53 (Fig. 3C). These data suggest that ZBTB2may inhibit tran-
scription of the p21 gene by directly acting on the distal p53
binding elements.
EMSA showed that the zinc finger DNA binding domain of
ZBTB2 could bind to p53 RE-1 and 2, suggesting a potential
binding competition between p53 and ZBTB2 (Fig. 3D). We
investigated whether the two proteins competed with each
FIGURE 3. ZBTB2 represses transcription of the p21 gene by binding competition with p53 to the distal p53 binding elements in vivo. A, transcription
analysis. MB352 cells lacking p53were transiently co-transfected with expression vector of p53 and/or ZBTB2 and pGL2-p21-Luc Wt (2.3 kb), and luciferase
activity was measured. B, transcription analysis in human HEK293A cells. Etoposide treatment of cells increased p21 gene transcription, which was repressed
by ZBTB2. C, transcriptional activation of pGL2–6x(p53RE)-Luc by ectopic p53 was repressed by ZBTB2 in Saos-2 cells lacking p53. p53RE, distal p53-binding
elements of the p21 gene promoter. D, EMSA. Two 32P-labeled p53 binding element probes of the p21 gene were incubated with GST-ZFZBTB2 (0.5 g) and
separated by 4% nondenaturing PAGE. E, ChIP assay of ZBTB2 binding on the distal p53 binding elements of the endogenous p21 gene in Saos-2 cells lacking
p53. The cellswere transfectedwithp53expression vector and increasing amounts of FLAG-ZBTB2expression vector. F, left, ChIP assayof ZBTB2bindingon the
distal p53 binding elements of the endogenous p21 gene in HEK293A cells. Cells were transfectedwith increasing amounts of FLAG-ZBTB2 expression vector.
Right, histograms of ZBTB2 and p53 binding on p53 binding elements 1 and 2.G, ChIP assay of endogenous ZBTB2 binding to the distal p53 binding elements
of the endogenous p21gene inHEK293A cells.H, oligonucleotide pull-downassay of endogenous ZBTB2binding to the distal p53binding elements of the p21
gene.WB, Western blot; IP, immunoprecipitation; Ab, antibody.
FIGURE 4. ZBTB2 interacts directly with p53 and inhibits p53 binding by protein-protein interactions.
A, ChIP assay of ZBTB2 binding on the proximal promoter of pG13-Luc in Saos-2 cells. Although ZBTB2 itself
couldnotbind to this p53bindingelement (5-CCAGGCAAGTCCAGGCAGG-3), its presence still decreasedp53
binding. B, co-immunoprecipitation of ZBTB2 and p53. HEK293A cell lysates prepared from cells transfected
with FLAG-ZBTB2 expression vector were immunoprecipitated (IP) using anti-FLAG antibody and analyzed by
Western blotting (WB) using anti-p53 antibody. C, in vitro GST fusion protein pull-down assay. Recombinant
GST, GST-POZZBTB2, or GST-ZFZBTB2 was incubated with [35S]methionine-labeled p53, pulled down, and
resolved by 10%SDS-PAGE. The gel was then exposed to x-ray film. Input, 10%of the p53 added in the binding
reactions. Ab, antibody.
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other for the sites of the endogenous p21 gene using ChIP
assays. Expression vectors of ZBTB2 and p53 were transiently
co-transfected in Saos2 cells lacking p53. ZBTB2 bound to p53
RE-1 by competing with p53 in a dose-dependent manner, but
binding competition between ZBTB2 and p53 at p53 RE-2 was
less pronounced (Fig. 3E). We found a similar binding compe-
tition between ZBTB2 and p53 on the endogenous p21 gene
promoter inHEK293A cells, and again the binding competition
on p53 RE-2 by ZBTB2 was also less effective (Fig. 3F).
Using newly prepared antibody against ZBTB2, we also
investigated whether endogenous ZBTB2 could bind to the dis-
tal p53 binding elements of the endogenous p21 gene using
ChIP and oligonucleotide pull-down assays. ZBTB2 binds spe-
cifically to p53 RE-1 and p53 RE-2 (Fig. 3, G and H).
We then used ChIP to determine whether ZBTB2 and p53
competed with each other on the well characterized pG13-Luc,
which has 13 copies of the p53 binding element (5-CCAG-
GCAAGTCCAGGCAGG-3) in the proximal promoter (24).
Expression vectors of ZBTB2, p53, andpG13-Luc reporter plas-
mids were transiently co-transfected in p53-null Saos2 cells,
and chromatin was immunoprecipitated using the indicated
antibodies. Contrary to our expectations, ZBTB2 did not
bind to the pG13-Luc reporter gene, possibly reflecting the
binding specificity of ZBTB2 to only some p53 binding
sequences (such as those of the p21 gene). ZBTB2 did, how-
ever, decrease p53 binding to the pG13-Luc reporter gene
quite effectively (Fig. 4A). The data suggest that ZBTB2 may
repress transcription of the p21 gene by directly interacting
with p53, and thus interfering with p53 binding on the prox-
imal promoter of pG13-Luc. Co-immunoprecipitation and
Western blot assays of HEK293A cells transfected with the
FLAG-ZBTB2 expression vector revealed that ZBTB2 and
p53 interact with each other in vivo (Fig. 4B). GST fusion
protein pull-down assay also showed that the GST-
ZFZBTB2 domain, not GST-POZZBTB2, interacted with
p53 in vitro, suggesting that p53 and ZBTB2 interact directly
with p53 via its zinc fingers of ZBTB2 (Fig. 4C).
The POZ Domain of ZBTB2 Interacts with the Corepressor-
HDAC Complex to Deacetylate Histones Ac-H3 and -H4 at the
Proximal Promoter—ZBTB2 repressed transcription by direct
binding competition with transcription activators such as Sp1
and p53, but it was not clear how it repressed transcription once
bound to the proximal and/or distal regulatory elements. To
map the domain of ZBTB2 important in transcription repres-
sion, we prepared a mutated ZBTB2 construct with the POZ
domain deleted (ZBTB2POZ). ZBTB2 repressed transcrip-
tion of the p21 gene but themutant ZBTB2POZ did not, indi-
cating that the POZ domain of ZBTB2 is required in transcrip-
tional repression (Fig. 5A).
Transcriptional repressors, including some POZ domain
proteins such as PLZF and BCL-6, often repress transcription
through interaction with corepressors such as SMRT, NCoR,
BCoR, and mSin3A. Mammalian two-hybrid assays in CV-1
cells using pG5-Luc, pGal4-POZZBTB2, and pVP16-corepres-
sor fusion protein expression vectors demonstrated that the
POZdomain of ZBTB2 interacts with SMRT,NCoR, and BCoR
(Fig. 5B). In addition, GST fusion protein pull-down assays
showed that POZZBTB2 can interact directly with SMRT,
NCoR, and BCoR (Fig. 5C). Corepressor complexes recruited
by transcriptional repressors often contain HDAC proteins.
These HDACs deacetylate the histones of nearby nucleosomes
to repress transcription. Co-immunoprecipitation and Western
blot analysis ofHEK293Acell extracts transfectedwith the FLAG-
ZBTB2 expression vector using anti-SMRT and anti-HDAC3
antibodies revealed that ZBTB2 and SMRT-HDAC interacted
with each other in vivo (Fig. 5D), indicating that ZBTB2 may
repress transcription of the p21 gene by interacting directly with
the corepressor-HDAC complex via its POZ domain.
HDAC inhibitor trichostatin A treatment of CV-1 or
HEK293A cells co-transfected with pG5-Luc and pGal4-
POZZBTB2 or pGL2-p21-Luc and ZBTB2 expression vectors
significantly affected transcriptional repression by ZBTB2 or
the POZ domain of ZBTB2 on both pG5-Luc and pGL2-p21-
Luc, resulting in a significant increase in transcription (Fig. 5, F
and G). These data implicate the involvement of HDACs in
transcriptional repression by ZBTB2.
Corepressor-HDACs recruited by the repressors may
deacetylate the histones of nearby nucleosomes around the
proximal promoter. Accordingly, we used ChIP to examine
whether the acetylation status of histones H3 and H4 at the
proximal promoter of the endogenous p21 gene was altered by
ZBTB2-corepressor-HDACs complexes in HEK293A cells
transfected with the FLAG-ZBTB2 expression vector. The
complex significantly decreased acetylated histones H3 and H4
at proximal promoter 4 (Fig. 5H).
ZBTB2 Stimulates HeLa Cell Proliferation and Increases the
Percentage of Cells in S-phase—A major regulator of cell cycle
arrest, p21,waspotently repressedbyZBTB2at the transcriptional
level. HeLa cells stably expressing ZBTB2 showed a significant
increase in cell proliferation (Fig. 6A). MTT assays revealed that
whereas ZBTB2 overexpression significantly increased cell prolif-
eration, ZBTB2 knock-down by siRNA decreased cell prolifera-
tion in the presence or absence of p53 (Fig. 6,B–F). FACS analysis
also showed that ZBTB2 stimulated cell cycle progression and
FIGURE 5. The POZ domain of ZBTB2 is important in transcription repression and interacts directly with corepressors. ZBTB2-corepressor-HDAC
complexes deacetylate histones Ac-H3 and -H4. A, transcription assays. The reporter pGL2-p21-Luc and expression plasmids of ZBTB2 or its POZ domain
deletion mutant ZBTB2POZ, were transiently co-transfected into HEK293A cells and luciferase activity was measured. B, mammalian two-hybrid assays of
protein-protein interactions between the POZ domain and corepressor proteins. CV-1 cells were transfected with pG5-Luc, pGal4-POZZBTB2, and pVP16-
corepressor expressionplasmids and luciferase activitywasmeasured.C, in vitroGST fusionprotein pull-downassays. RecombinantGSTorGST-POZZBTB2was
incubated with [35S]methionine-labeled corepressors, pulled down, and resolved by 10% SDS-PAGE. The gel was then exposed to x-ray film. Input, 10% of the
corepressors added in thebinding reactions.D, co-immunoprecipitationofZBTB2andSMRT-HDAC3.Cell lysatesprepared fromHEK293Acells transfectedwith
FLAG-ZBTB2 expression vector were immunoprecipitated (IP) using anti-FLAG antibody and analyzed by Western blotting (WB) using anti-SMRT and HDAC3
antibodies. E and F, trichostatin A (TSA) treatment derepressed transcription repression of pG5-Luc andpGL2-p21-Luc by the POZdomain or full-length ZBTB2.
Plasmidmixtures of pG5-Luc and thepGal4-POZZBTB2expressionplasmidorpGL2-p21-Luc and theZBTB2expressionplasmidwere transiently co-transfected
into CV-1 or HEK293A cells. G, left, ChIP assays of histonemodification at the proximal promoter of the endogenous p21 gene using antibodies against Ac-H3
and -H4. Cells were transfected with FLAG-ZBTB2 and immunoprecipitated with the indicated antibodies. Right, histogram of ChIP assays. Ab, antibody.
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increased the number ofHEK293A cells in S-phase (38.3% in con-
trol versus48.5% inHEK293A-ZBTB2). Furthermore, thenumber
of cells in the G2-M phase decreased from 5.7 to 0% (Fig. 6G).
Knock-downof endogenousZBTB2mRNAresulted in a decrease
in thenumberof cells inS-phaseandaconcomitant increase in the
number of cells in G0-G1 and G2-M phases (Fig. 6H). We also
observed similar changes in cell cycle progression in the presence
of p53, and ZBTB2 reversed the cell cycle arrest effect of p53 as in
theMTT assays (Fig. 6I).
DISCUSSION
Our investigation revealed that ZBTB2 represses transcrip-
tion ofARF, p53, and p21 and activates transcription ofHDM2.
Potent repression ofARF and activation of theHDM2 gene can
FIGURE 6. ZBTB2 stimulates cell proliferation and cell cycle progression. A, foci-formation assays. HeLa cells transfected with the ZBTB2 expression
vector were cultured in G418 medium and stained with 0.1% crystal violet. HeLa cells stably expressing ZBTB2 showed an increase in cell proliferation.
B and C, MTT assay of HEK293A cells grown for 2, 4, or 6 days. Cells were transfected with either the control vector or ZBTB2 expression vector and
analyzed for cell growth. Alternatively, cells were treatedwith either negative control siRNA or ZBTB2 siRNA. All assays were performed in triplicate. Error bars are
included but too tight to see. p values are0.001.D, Western blot (W.B.) analysis. HEK293A cells were transfectedwith the expression vector of FLAG-ZBTB2 and/or
Myc-p53.And thecell extractswereanalyzed forp21,p53, andZBTB2expression.GAPDH, control.EandF,MTTassay.Cellswere transfectedwitheither control vector
or ZBTB2expression vector in the absenceorpresenceof p53expression vector andanalyzed for cell growth. Assayswereperformedas inB andC.G–I, FACSanalysis
ofcell cycleprogression.HEK293AcellsweretransfectedwithZBTB2expressionvectororcontrolvector,cultured,andstainedwithpropidiumiodide.Cellproliferation
wasmeasured by FACS. Alternatively, cells were transfected with siRNA against ZBTB2mRNA and cell cycle progression was analyzed. The same FACS analysis was
performed after cells were transfectedwith orwithout p53 expression vector.Mock, transfectionwithout siRNA.N.C., scrambled negative control siRNA.
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result in an overall increase in HDM2 gene expression, which
can decrease p53 activity or stability. Themechanismof repres-
sion of the p53 pathway by ZBTB2 is directed toward the inhi-
bition of p53 activity or stability. In addition to potently mod-
ulating expression of ARF and HDM2 and thereby eventually
affecting p21 expression by down-regulating p53 expression,
ZBTB2 directly repressed transcription of the p21 gene (Fig.
7A). Although details of the transcription regulation of ARF,
p53, and HDM2 by ZBTB2 remains largely unexplored and
requires further investigation, ZBTB2 may be a master control
gene of the p53 pathway and thus of cell proliferation, cell cycle
progression, and oncogenesis.
Our investigation of regulation of the cell cycle arrest gene
p21 revealed that p21 is the direct target of ZBTB2, with a com-
plex molecular mechanism of transcription repression that
involves Sp1, p53, proximal GC-box 5/6, and two distal p53
binding elements of p21. ZBTB2 competes with Sp1 to bind to
the proximal Sp1 bindingGC-box 5/6,which is a direct target of
regulation by Sp1 and Sp family members. Intriguingly, ZBTB2
binds to this particular site to repress transcription activation
by Sp1.
Our data also showed that ZBTB2 binds to distal p53 binding
elements by competingwith p53, and that ZBTB2 also interacts
with p53 directly to inhibit p53 binding and to repress the con-
tribution of p53 to transcription. The sitewas shown tomediate
the induction of p21 by genotoxic stresses. Accordingly, DNA
damaging signals that result in p53-medicated induction of p21
can be blocked by ZBTB2. Overall, these molecular features of
ZBTB2 may explain how ZBTB2 acts as a master control gene
of cell proliferation by potently blocking the p53 pathway.
Based on our finding, we propose a hypothetical model of
transcriptional regulation of the p21 gene by ZBTB2 (Fig. 7).
Under normal cellular conditions where p53 is expressed at low
basal levels and ZBTB2 is not present or low compared with
Sp1, the p21 gene is expressed at low basal levels driven by Sp1,
and cells proliferate normally. Challengewith a genotoxic stress
induces production of tumor suppressor p53, which binds to
the distal p53 response elements and activates transcription of
p21 by interacting with the Sp1 bound at the proximal GC-box.
The induced p21 arrests cell cycle progression, allowing cells to
repair DNA damage. In cells without DNA damage where
ZBTB2 expression is high, ZBTB2 represses transcription
FIGURE7.Hypotheticalmodelof transcriptional regulationof thep21geneandp53pathway.A, p53pathwayandZBTB2 targets. ZBTB2 repressed transcription
of the ARF, p53, and p21 genes and activated HDM2 gene transcription. Solid line with arrowhead (3), transcriptional activation; solid line with, transcriptional
repression. Solid line with double arrowhead (7), molecular interaction; *, inhibition of transcription factor binding. B, hypothetical model of transcriptional
regulation of p21 by ZBTB2 under three different cellular conditions. ZBTB2 represses transcription of the cell cycle arrest gene p21 by binding to the proximal
GC-box 5/6 elements and the twodistal p53 binding elements by competitionwith either Sp1 and/or p53. ZBTB2 interactswith p53 via its zinc fingers and also
interacts with Sp1 via its POZ domain and zinc fingers. These protein-protein interactions inhibit Sp1 or p53 binding to their respective binding elements.
ZBTB2 attacks the three critical elements that are important in basal constitutive and inducible expression. ZBTB2 recruits co-repressor-HDAC complexes,
which deacetylate histones Ac-H3 and -H4 at the proximal promoter to repress transcription. Tsp (1), transcription start site.
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directly by binding to both the proximal GC-box 5/6 and distal
p53 binding elements. ZBTB2 bound to the regulatory ele-
ments recruits the corepressor-HDAC complex, causing
deacetylation of histones Ac-H3 and -H4 around the proximal
promoter and repressing transcription. When cells are under
genotoxic stress and ZBTB2 expression is high or in cancerous
tissues that have high levels of p53 and ZBTB2, ZBTB2
represses transcription directly by binding to both the proximal
GC-box 5/6 and distal p53 binding elements. Although p53
expression is also highly induced under these conditions, p53
has to compete with ZBTB2 to bind to the distal p53 binding
elements and is also affected bymolecular interactions between
p53 and ZBTB2 that further impede binding. Although p53 is
present, transcription of the p21 gene is potently repressed by
ZBTB2. Cells proliferate without cell cycle arrest, mutations
accumulate, and cells are likely to undergo oncogenic
transformation.
ZBTB2 has characteristics of Sp1-family Kru¨ppel-like zinc
finger proteins and binds to some of the GC-boxes that are
similar to the GC-boxes recognized by Sp1. This finding sug-
gests that GC-boxes recognized by Sp1 may be transcriptional
repression targets of ZBTB2, and that Sp1-ZBTB2 binding
competition may be a general mechanism of transcriptional
repression of someZBTB2 target genes.Molecular interactions
occurring both in the proximal and distal promoter of the p21
gene are unique and may be also relevant to the transcription
regulation of other genes of the Arf-HDM2-p53-p21 pathway.
How ZBTB2 potently activates (as much as 80-fold under our
assay conditions) transcription of theHDM2 gene (which has a
p53 binding element in the P2 promoter and is activated by p53)
remains unclear and needs further investigation. The strong
induction of the HDM2 gene may induce rapid degradation of
p53, significantly blocking the protective effect of p53 in the
cellular response toDNAdamage. Taken together, our findings
suggest that ZBTB2may play a critical role in regulating impor-
tant biological processes such as DNA repair, cell growth, dif-
ferentiation, and apoptosis by regulating the transcription of
p21 and other genes of the p53 pathway.
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